SLG
LGND icon

Stanley-Laman Group’s Ligand Pharmaceuticals LGND Stock Holding History

Stanley-Laman Group’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-4,809
Closed -$321K – 295
2016
Q1 		$321K Hold
4,809
– – 0.06% 207
2015
Q4 		$325K Hold
4,809
– – 0.06% 259
2015
Q3 		$257K Hold
4,809
– – 0.05% 261
2015
Q2 		$303K Hold
4,809
– – 0.06% 247
2015
Q1 		$231K Buy
+4,809
New +$184K 0.04% 278
2014
Q2 		– Sell
-4,809
Closed -$202K – 297
2014
Q1 		$202K Buy
+4,809
New +$200K 0.04% 306

Other funds holding LGND

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Stanley-Laman Group's LGND Position: Q2 2016 in Review

Stanley-Laman Group sold out of Ligand Pharmaceuticals (LGND) in Q2 2016, closing a stake of 4,809 shares — an estimated $321K sold.

Stanley-Laman Group first reported a position in LGND in Q1 2014 and held it in 6 quarters. The position peaked at $325K in Q4 2015. 265 funds tracked by Wall St. Rank hold LGND as of Q2 2016.

  • Stanley-Laman Group reported no remaining Ligand Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Stanley-Laman Group sold 4,809 Ligand Pharmaceuticals shares in Q2 2016, an estimated $321K.
  • Stanley-Laman Group first reported a position in Ligand Pharmaceuticals in Q1 2014 and held it in 6 quarters.
  • Stanley-Laman Group's Ligand Pharmaceuticals position peaked at $325K in Q4 2015.
  • 265 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2016.

Based on Stanley-Laman Group's 13F filing for Q2 2016, filed 4 Aug 2016.